Sarah E Rowan, Marcos C. Schechter, Jennifer Dolan Thomas, Kevin O'Laughlin, Tracy Scott, Halie K. Miller, Juliana Almeida da Silva, Ashley Paulick, Talya Shragai, Jesse J Carlson, Cdc Covid Response Lab Task Force, D. Joseph Sexton, Hannah L Kirking, Courtney C. Nawrocki, Grace E Marx, Mitsuki Koh, Jacqueline E. Tate, Hany Atallah, Yun F. Wang, Brad J. Biggerstaff, Emily A. Travanty, Karen A. Wendel, Sarah E. Smith-Jeffcoat, Rebekah J Stewart, Claire Hartloge, Brooks Moore, Alexis Burakoff, Rebecca Rosetti, Sarah E. Totten, Jesse Chavez-Van De Hey, Cdc Covid Emergency Response Ga Field Team, Paulina A. Rebolledo, Adam Hoffman, Caitlin Biedron, and Sadia Sleweon
Nasopharyngeal swabs (NPS) collected by trained healthcare professionals are the preferred specimen for SARS-CoV-2 testing. Self-collected specimens might decrease patient discomfort, conserve healthcare resources, and be preferred by patients. During August – November 2020, 1,806 adults undergoing SARS-CoV-2 testing in Denver, Colorado and Atlanta, Georgia, provided self-collected anterior nares swabs (ANS) and saliva specimens before NPS collection. Compared to NPS, sensitivity for SARS-CoV-2 detection by rRT-PCR appeared higher for saliva than for ANS (85% versus 80% in Denver; 67% versus 58% in Atlanta) and higher among participants reporting current symptoms (94% and 87% in Denver; 72% and 62% in Atlanta, for saliva and ANS, respectively) than among those reporting no symptoms (29% and 50% in Denver; 50% and 44% in Atlanta, for saliva and ANS, respectively). Compared to ANS, saliva was more challenging to collect and process. Self-collected saliva and ANS are less sensitive than NPS for SARS-CoV-2 detection; however, they offer practical advantages and might be most useful for currently symptomatic patients.